reports
- Cor Kluis
- Thomas Zlowodzki
- Cor Kluis
- Thomas Zlowodzki
- Hans D’Haese
- Maxime Stranart
Ahold Delhaize/2Q25 results: EPS guidance still at risk due to FX/HOLD
We reiterate our HOLD rating on Ahold Delhaize but lower our target price from €36 to €35, as we reduce our top- and bottom-line forecasts on higher FX headwinds. We remain cautious on Ahold Delhaize USA's organic growth, noting the ongoing price investment programme while inflation starts to build, as highlighted by market leader Walmart in its 2Q release. Consensus continues to see flat underlying operating profit in the country (excl. FX), while we remain more cautious there. This leads us to...
- ING Helpdesk
- Jan Frederik Slijkerman
Telecom Italia 2Q25 results/Cash generation disappoints, so far
Telecom Italia[e] reported good underlying results, however, we were disappointed by the results on a reported basis as well as by cash flow generation. Based on provided guidance, financials will improve. Nevertheless, we doubt Telecom Italia will be investment grade rated in the near future.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of th...
- ING Helpdesk
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity. The accelerated approval is based...
- Maissa Keskes
- Stephane Houri
EVT EVOTEC SE
GYC GRAND CITY PROPERTIES SA
TPE PVA TEPLA AG
GLB GLANBIA PLC
LNZ LENZING AG
SIX2 SIXT SE
FTON FEINTOOL INTERNATIONAL HOLDING AG
WIE WIENERBERGER AG
SEM SEMPERIT HOLDING AG
PAT PATRIZIA AG
KTCG KAPSCH TRAFFICCOM
FYB FORMYCON AG
JEN JENOPTIK AG
HGEA HGEARS AG
TUI TUI AG
R3NK RENK GROUP AG
AQ AQUILA PART PROD COM
SPG SPRINGER NATURE AG & CO. KGAA
- Maissa Keskes
- Stephane Houri
EVT EVOTEC SE
GYC GRAND CITY PROPERTIES SA
TPE PVA TEPLA AG
GLB GLANBIA PLC
LNZ LENZING AG
SIX2 SIXT SE
FTON FEINTOOL INTERNATIONAL HOLDING AG
WIE WIENERBERGER AG
SEM SEMPERIT HOLDING AG
PAT PATRIZIA AG
KTCG KAPSCH TRAFFICCOM
FYB FORMYCON AG
JEN JENOPTIK AG
HGEA HGEARS AG
TUI TUI AG
R3NK RENK GROUP AG
AQ AQUILA PART PROD COM
SPG SPRINGER NATURE AG & CO. KGAA
- Christophe Chaput
- Hela Zarrouk
- Christophe Chaput
- Hela Zarrouk
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 12 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of th...
- Julian Dobrovolschi
- Julian Dobrovolschi
- Emna Ben Bdira
- Maxime Kogge
- Emna Ben Bdira
- Maxime Kogge
- Julian Dobrovolschi
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.